EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis

Nicholas A Tritos, Martin O Carlsson, Greisa Vila, Camilo Jimenez, Daria La Torre, Michael P Wajnrajch, Beverly M K Biller, Lissette Cespedes, Karen K Miller

Endocrine Connections · 2025-09-01 · 14 (9)

DOI: 10.1530/ec-25-0247 ↗
AbstractBibliografische Angaben

Abstract

Graphical Abstract Abstract Objective Characterize disease-specific mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including on-therapy insulin-like growth factor I (IGF-I) levels. Design Retrospective cohort analysis of ACROSTUDY, a global surveillance study of patients with acromegaly receiving pegvisomant. Methods Cumulative incidence function was used to estimate disease-specific mortality, and regression analyses to characterized risk factors. Disease-specific standardized mortality ratios (SMR) were calculated; Poisson regression models characterized the association between disease-specific SMR, IGF-I, and other risk factors. Results 2077 patients were followed (median: 4.1 years). Mortality (HR, 95% CI) secondary to cardiovascular/cerebrovascular causes increased with higher on-treatment IGF-I (1.97 (1.45–2.67), P < 0.0001) and older age at enrollment (1.10 (1.07–1.13), P < 0.0001). Mortality secondary to malignant (1.57 (1.17–2.09), P = 0.0024) or respiratory (1.64 (1.23–2.19), P = 0.0008) causes increased with higher on-treatment IGF-I. Younger attained age (0.93 (0.91–0.96), P < 0.0001), younger age (<35 vs > 50 years) at diagnosis (3.64 (1.33–9.93), P = 0.0117), higher on-treatment IGF-I (1.69 (1.12–2.55), P = 0.0127), and pituitary radiotherapy (2.25 (1.09–4.63), P = 0.0280) were associated with higher SMR (95% CI) for cardiovascular/cerebrovascular causes. Younger attained age (0.93 (0.89–0.96), P < 0.0001), higher IGF-I at enrollment (>2 × vs <1 × upper limit of normal: 4.89 (1.09–21.8), P = 0.0378), and malignancy at enrollment (7.05 (2.36–21.03), P = 0.0005) were associated with higher SMR (95% CI) for malignant causes. Younger age (35–50 vs >50 years) at diagnosis (4.50 (1.08–18.83), P = 0.0394) and sleep apnea (4.98 (1.34–18.53), P = 0.0168) were associated with higher SMR ratios for respiratory causes. Conclusions Younger age, higher on-therapy IGF-I, and radiotherapy were associated with higher SMR for cardiovascular/cerebrovascular causes, highlighting the importance of achieving IGF-I normalization.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →